JPH0840B2 - Active oxygen suppressing composition, method for producing the same, and blood pressure suppressing agent - Google Patents
Active oxygen suppressing composition, method for producing the same, and blood pressure suppressing agentInfo
- Publication number
- JPH0840B2 JPH0840B2 JP4199082A JP19908292A JPH0840B2 JP H0840 B2 JPH0840 B2 JP H0840B2 JP 4199082 A JP4199082 A JP 4199082A JP 19908292 A JP19908292 A JP 19908292A JP H0840 B2 JPH0840 B2 JP H0840B2
- Authority
- JP
- Japan
- Prior art keywords
- water
- active oxygen
- aqueous solution
- weight
- evaporation residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims description 36
- 229910052760 oxygen Inorganic materials 0.000 title claims description 36
- 239000001301 oxygen Substances 0.000 title claims description 36
- 230000036772 blood pressure Effects 0.000 title claims description 32
- 239000000203 mixture Substances 0.000 title claims description 28
- 239000003795 chemical substances by application Substances 0.000 title claims description 14
- 238000004519 manufacturing process Methods 0.000 title claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 37
- 229940094952 green tea extract Drugs 0.000 claims description 27
- 235000020688 green tea extract Nutrition 0.000 claims description 27
- 238000000855 fermentation Methods 0.000 claims description 26
- 230000004151 fermentation Effects 0.000 claims description 26
- 238000001704 evaporation Methods 0.000 claims description 22
- 230000008020 evaporation Effects 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 244000068988 Glycine max Species 0.000 claims description 14
- 235000010469 Glycine max Nutrition 0.000 claims description 14
- 241000209094 Oryza Species 0.000 claims description 14
- 235000007164 Oryza sativa Nutrition 0.000 claims description 14
- 235000009566 rice Nutrition 0.000 claims description 14
- 239000000284 extract Substances 0.000 claims description 13
- 244000063299 Bacillus subtilis Species 0.000 claims description 9
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 2
- 235000013557 nattō Nutrition 0.000 claims 2
- 230000000694 effects Effects 0.000 description 26
- 238000012360 testing method Methods 0.000 description 26
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 102000019197 Superoxide Dismutase Human genes 0.000 description 10
- 108010012715 Superoxide dismutase Proteins 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 8
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 229940068041 phytic acid Drugs 0.000 description 8
- 235000002949 phytic acid Nutrition 0.000 description 8
- 239000000467 phytic acid Substances 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000019362 perlite Nutrition 0.000 description 3
- 239000010451 perlite Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 238000004435 EPR spectroscopy Methods 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VCUVETGKTILCLC-UHFFFAOYSA-N 5,5-dimethyl-1-pyrroline N-oxide Chemical compound CC1(C)CCC=[N+]1[O-] VCUVETGKTILCLC-UHFFFAOYSA-N 0.000 description 1
- 241000156724 Antirhea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 241001131796 Botaurus stellaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000002802 cardiorespiratory effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000010006 flight Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002895 organic esters Chemical group 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003018 phosphorus compounds Chemical class 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cereal-Derived Products (AREA)
- Tea And Coffee (AREA)
- Medicines Containing Plant Substances (AREA)
Description
【0001】[0001]
【産業上の利用分野】本発明は、活性酸素抑制組成物及
びその製造方法並びに血圧抑制剤に関する。本発明は、
活性酸素(O2 −)が原因となる各種の病気、例えば、
血流障害による病気(心筋梗塞、脳卒中、高血圧、生理
痛、肩こり、神経痛、腰痛、二日酔い等)、成人病・内
科疾患(癌、腎炎、肝炎、糖尿病等)、美容・皮膚病
(しみ、そばかす、肌荒れ、冷え症、便秘、しわ、アト
ピー性皮膚炎等)等の治療、改良等に広く利用される。TECHNICAL FIELD The present invention relates to a composition for suppressing active oxygen, a method for producing the same, and a blood pressure suppressing agent. The present invention
Various diseases caused by active oxygen (O 2 − ), for example,
Diseases caused by blood flow disorders (myocardial infarction, stroke, high blood pressure, menstrual cramps, stiff shoulders, neuralgia, back pain, hangover, etc.), adult diseases / internal diseases (cancer, nephritis, hepatitis, diabetes, etc.), beauty / skin diseases (stains, freckles) , Rough skin, chills, constipation, wrinkles, atopic dermatitis, etc.) are widely used for treatment and improvement.
【0002】[0002]
【従来の技術】スーパーオキシドジスムターゼ(SOD
という。)は、酸素分子の1電子還元で生成するスーパ
ーオキシドラジカル(superoxide radi
cal,O2 −)の不均化反応(下式)を拡散律速に近
い速さで触媒し、細胞内のO2 −濃度を低下させる酵素
である。 O2 −+O2 −+2H+→H2O2+O2 近年、O2 −が生体に有害ならば、その除去酵素である
このSODは、生体を活性酸素毒性から守るために存在
する筈のものであり、従って、この活性酸素を起因とし
て生じると考えられる病気等に有用であるとの観点か
ら、その反応機構、生理機構等が研究されている〔「活
性酸素−生物での生成・消去・作用の分子機構」(新装
版2刷、共立出版株式会社発行、中野稔ら編著)P.2
23〜230)〕。また、癌細胞では活性酸素抑制活性
が低いという事実があり、更に、SODと発癌との直接
因果関係は明らかではないが、SOD又はSOD様物質
を癌細胞に注入すると、増殖を抑えるという報告(記
述)もある(同、P.64)。2. Description of the Related Art Superoxide dismutase (SOD
Say. ) Is a superoxide produced by one-electron reduction of oxygen molecule
-Oxide radical
cal, O2 −) Disproportionation reaction (equation below)
It catalyzes at a high speed and intracellular O2 −Enzyme that reduces concentration
Is. O2 −+ O2 −+ 2H+→ H2O2+ O2 In recent years, O2 −If is harmful to the living body, it is its removal enzyme
This SOD exists to protect the living body from active oxygen toxicity.
This active oxygen is the cause.
From the perspective that it is useful for diseases that are thought to occur
Have studied the reaction mechanism, physiological mechanism, etc.
Oxygen-Molecular mechanism of generation, elimination and action in living organisms "
Second edition, published by Kyoritsu Shuppan Co., Ltd., edited by Minoru Nakano et al.) 2
23-230)]. In addition, active oxygen suppression activity in cancer cells
The fact that the SOD is low, and moreover, the direct relationship between SOD and carcinogenesis
The causal relationship is not clear, but SOD or SOD-like substances
It is reported that the injection of cancer cells into cancer cells suppresses their growth.
(P.64).
【0003】[0003]
【発明が解決しようとする課題】安全で且つ活性酸素抑
制作用のある食品(組成物)があれば、人の健康及び美
容にとって、極めて有用なものとなり、その必要性は極
めて大きい。特に、近年のようにストレスが多く且つ多
くの病気が発生している状況においては、特に、その必
要性が大きい。If there is a food (composition) that is safe and has an active oxygen suppressing action, it will be extremely useful for human health and beauty, and there is a great need for it. In particular, in a situation where stress is high and many diseases are occurring as in recent years, the necessity thereof is great.
【0004】本発明は、米糠類及び大豆類を原料として
用い、7.5〜10のpHにて発酵させて得た発酵水溶
液に、水溶性緑茶抽出エキスを含有させてなる、安全で
且つ優れた活性酸素抑制作用を有する組成物及びその製
造方法並びに血圧抑制剤を提供することを目的とする。The present invention is a safe and excellent method in which a water-soluble green tea extract is contained in a fermentation aqueous solution obtained by fermenting rice bran and soybeans as raw materials at a pH of 7.5 to 10. Another object of the present invention is to provide a composition having an active oxygen suppressing action, a method for producing the same, and a blood pressure suppressing agent.
【0005】[0005]
【課題を解決するための手段】以上の観点より、本発明
者等は、この活性酸素抑制作用を有する組成物及び血圧
抑制剤として、安全な発酵物を利用したものはないか等
について、鋭意、種々検討した所、上記発酵水溶液に水
溶性緑茶抽出エキスを配合することにより、その目的を
達成できることを発見して、本発明を完成するに至った
ものである。本第1発明の活性酸素抑制組成物は、米糠
類、大豆類及び水を含み、アルカリ剤にてpHを7.5
〜10に調整された液体培地に納豆菌若しくは枯草菌を
接種し、好気性雰囲気下において培養させ、濾過して製
造した発酵水溶液又は該発酵水溶液の蒸発残分に、水及
びエタノールのうちの少なくとも1種を含む溶媒にて抽
出してなる水溶性緑茶抽出エキス又は該水溶性緑茶抽出
エキスの蒸発残分を含有させてなることを特徴とする。
また、第3発明は水溶液状の活性酸素抑制組成物を製造
する方法であり、第7発明は第1発明の活性酸素抑制組
成物を血圧抑制剤として利用したものである。From the above viewpoints, the inventors of the present invention diligently investigated whether a composition containing this active oxygen-inhibiting effect and a blood pressure-suppressing agent utilize a safe fermented product. As a result of various studies, the present invention has been completed by discovering that the purpose can be achieved by adding a water-soluble green tea extract to the above fermented aqueous solution. The active oxygen inhibiting composition of the first invention contains rice bran, soybeans and water, and has a pH of 7.5 with an alkaline agent.
Inoculation of Bacillus subtilis or Bacillus subtilis into a liquid medium adjusted to -10, culturing in an aerobic atmosphere, and a fermentation aqueous solution produced by filtration or an evaporation residue of the fermentation aqueous solution, at least water and ethanol. It is characterized by containing a water-soluble green tea extract extract obtained by extraction with a solvent containing one kind or an evaporation residue of the water-soluble green tea extract extract.
The third invention is a method for producing an active oxygen-suppressing composition in the form of an aqueous solution, and the seventh invention uses the active oxygen-suppressing composition of the first invention as a blood pressure suppressor.
【0006】この「緑茶抽出エキス」とは、茶葉から水
及びエタノールのうちの少なくとも1種を含む溶媒にて
抽出して水溶性のものとしたものであり、抽出成分の濃
度は、5〜50重量%程度とすることができる。そし
て、この緑茶抽出エキスの配合割合は、第2、第6及び
第8発明に示すように、その蒸発残分換算にて、上記発
酵水溶液の蒸発残分100重量部に対して1〜50重量
部とすることができる。これが、1重量部未満では、そ
の効果が十分に期待できないし、50重量部を越える
と、味覚的に飲用することが困難となるためである。The "green tea extract" is extracted from tea leaves with a solvent containing at least one of water and ethanol to make it water-soluble, and the concentration of the extracted components is 5 to 50. It can be about% by weight. Then, the mixing ratio of the green tea extract is, as shown in the second, sixth and eighth inventions, 1 to 50 parts by weight in terms of the evaporation residue, based on 100 parts by weight of the evaporation residue of the fermentation aqueous solution. It can be a department. This is because if it is less than 1 part by weight, the effect cannot be expected sufficiently, and if it exceeds 50 parts by weight, it becomes difficult to taste and drink.
【0007】また、発酵水溶液若しくはこの蒸発残分に
フラボイドを含有させた組成物とすることができる。こ
の「フラボノイド」は、広く植物界に分布しており、二
つのフェニル基がピラン環あるいはそれに近い構造の3
個の炭素原子をはさんで結合している、いわゆるC6−
C3−C6炭素骨格から成る化合物群である。このフラ
ボノイドは、緑茶抽出エキス中の蒸発残分に対して、1
3〜14重量%含まれている。そして、このフラボノイ
ドの配合割合は、発酵水溶液100重量部(例えばエキ
ス濃度が40〜50重量%の場合)に対して0.1〜7
重量部程度とすることができる。これが、0.1重量部
未満では、その効果が十分に期待できないし、7重量部
を越えると味覚的に飲用することが困難となるためであ
る。Further, a composition in which flavoid is contained in the fermentation aqueous solution or the evaporation residue can be prepared. This "flavonoid" is widely distributed in the plant kingdom, and two phenyl groups have a structure similar to or similar to the pyran ring.
So-called C 6 -bonded by sandwiching carbon atoms
It is a compound group consisting of C 3 -C 6 carbon skeleton. This flavonoid is 1 in the evaporation residue in the green tea extract.
It is contained in an amount of 3 to 14% by weight. And, the blending ratio of this flavonoid is 0.1 to 7 relative to 100 parts by weight of the fermented aqueous solution (for example, when the extract concentration is 40 to 50% by weight).
It can be about parts by weight. This is because if the amount is less than 0.1 part by weight, the effect cannot be expected sufficiently, and if it exceeds 7 parts by weight, it becomes difficult to taste and drink.
【0008】上記「米糠類」とは、米胚芽、脱脂米胚
芽、米糠、脱脂米糠等をいい、「大豆類」とは、脱脂大
豆、キナ粉、大豆粉、大豆カス、これらの加水分解物等
をいう。通常、これらの添加割合は、米糠類を100重
量部とする場合、大豆類が10〜20重量部である。ま
た、発酵に通常用いられるグルコース等の炭素源等の栄
養源を用いることもできる。この発酵条件は、通常、p
Hが7.5〜10(特に9前後)、培養温度が40〜4
5℃程度である。尚、培地原料としてはプロテアーゼを
用いることができる。この場合は、大豆ペプチドを更に
分解するので、有用である。The above-mentioned "rice bran" means rice germ, defatted rice germ, rice bran, defatted rice bran and the like, and "soybeans" means defatted soybean, quina flour, soybean flour, soybean dregs and hydrolysates thereof. Etc. Usually, these are added in an amount of 10 to 20 parts by weight of soybeans when the rice bran is 100 parts by weight. Further, a nutrient source such as a carbon source such as glucose usually used for fermentation can also be used. This fermentation condition is usually p
H is 7.5 to 10 (especially around 9), culture temperature is 40 to 4
It is about 5 ° C. In addition, protease can be used as a medium material. This case is useful because it further decomposes the soybean peptide.
【0009】上記「発酵水溶液」としては、培養させた
培養発酵水溶液を濾過したままの液でもよいし、これを
脱色等の後処理をした液でもよいし、これを濃縮した濃
縮液でもよい。尚、上記のように、この発酵水溶液の蒸
発残分(固形分)を用いてもよい。The above-mentioned "fermentation aqueous solution" may be a solution obtained by culturing a cultured and fermented aqueous solution as it is, a solution obtained by post-treatment such as decolorization, or a concentrated solution obtained by concentrating the solution. As described above, the evaporation residue (solid content) of this fermentation aqueous solution may be used.
【0010】また、水溶性緑茶抽出エキス若しくはこの
蒸発残分にフィチン酸及びその塩の少なくとも一方を含
有させた組成物とすることができる。上記「フィチン
酸」としては、合成フィチン酸でも、抽出単離したフィ
チン酸でもよい。また、「その塩」としては、非毒性塩
が用いられ、金属、有機塩基、塩基性アミノ酸、有機エ
ステル残基等との塩が用いられ、例えば、カリウム、ナ
トリウム、アルギニン、オルニチン、リジン、ヒスチジ
ン、グルカミン、モノエタノールアミン等の塩とするこ
とができる。このフィチン酸が酸性を示すことから、通
常、pHが6〜8程度のその塩を用いる。通常、この塩
は水溶性のものである。また、このフィチン酸及びその
塩類は、上記発酵水溶液に多く含まれており、リン濃度
より換算すると、この蒸発残分100重量部に対して、
フィチン酸相当物が6〜7重量部含まれている。従っ
て、フィチン酸等に所定量の緑茶抽出エキスを含有して
も、上記発明の場合と同様に、同等の効果が確実に得ら
れるものと考えられる。Further, a water-soluble green tea extract or a composition in which at least one of phytic acid and its salt is contained in the evaporation residue can be prepared. The above-mentioned "phytic acid" may be synthetic phytic acid or phytic acid extracted and isolated. Further, as "the salt", a non-toxic salt is used, and a salt with a metal, an organic base, a basic amino acid, an organic ester residue or the like is used, and examples thereof include potassium, sodium, arginine, ornithine, lysine, histidine. , Glucamine, monoethanolamine and the like. Since this phytic acid exhibits acidity, a salt thereof having a pH of about 6 to 8 is usually used. Usually, this salt is water-soluble. Further, this phytic acid and its salts are contained in large amounts in the above-mentioned fermented aqueous solution, and when converted from the phosphorus concentration, 100 parts by weight of this evaporation residue,
It contains 6 to 7 parts by weight of phytic acid equivalent. Therefore, it is considered that even if a predetermined amount of green tea extract is contained in phytic acid or the like, the same effect can be surely obtained as in the case of the above invention.
【0011】[0011]
【実施例】以下実施例により本発明を具体的に説明す
る。 (1)発酵水溶液の製造及び活性酸素抑制組成物及び血
圧抑制剤の試験品の調製 まず、以下に示す方法により発酵水溶液を製造する。即
ち、脱脂米糠;30kg、大豆かす(又は脱脂大豆);
3kg、苦汁;5kg、水;500kgを使用した。
尚、pHは9前後である。上記培地を121℃、30分
にて殺菌し、その後冷却し、次いで、納豆菌(製造元;
成瀬醗酵化学研究所)0.05Kgを接種し、40〜4
5℃にて約48時間、通気、撹拌して培養させた。The present invention will be described in detail with reference to the following examples. (1) Production of Fermentation Aqueous Solution and Preparation of Active Oxygen Suppressing Composition and Blood Pressure Suppressing Agent Test Product First, a fermentation aqueous solution is produced by the following method. That is, defatted rice bran; 30 kg, soybean meal (or defatted soybean);
3 kg, bittern, 5 kg, water; 500 kg were used.
The pH is around 9. The above medium was sterilized at 121 ° C. for 30 minutes, then cooled, and then Bacillus natto (manufacturer;
Naruse Fermentation Research Institute) inoculated with 0.05 kg, 40-4
The cells were cultivated by aeration and stirring at 5 ° C. for about 48 hours.
【0012】その後、この培養物を圧搾濾過し、活性炭
及びパーライトで処理をして脱臭、脱色をし、ほぼ透明
の発酵水溶液(発酵エキス)を得た。尚、この活性炭と
しては、粉末活性炭(活性炭S、活性炭K等)、粒状活
性炭(活性炭SG等)の種々のものを使用でき、パーラ
イトとしては、「パーライトNo.4180」(ダイカ
ラインオリエント(株)製)を使用した。この発酵水溶
液は、無色若しくは淡黄色の透明液体であり、発酵の香
味があり、水分92〜94%(常圧加熱乾燥法によ
る。)、リン約300〜400mg/100g(バナド
モリブデン分析方法による。)で、一般生菌、大腸菌、
カビ、酵母並びに砒素、鉛、カドミウム、スズは検出さ
れなかった。Then, this culture was squeezed and filtered, treated with activated carbon and perlite to deodorize and decolorize, and an almost transparent fermentation aqueous solution (fermented extract) was obtained. As the activated carbon, various types such as powdered activated carbon (activated carbon S, activated carbon K, etc.) and granular activated carbon (activated carbon SG, etc.) can be used, and as the perlite, “Perlite No. 4180” (Daikaline Orient Co., Ltd.) Manufactured) was used. This fermented aqueous solution is a colorless or pale yellow transparent liquid, has a flavor of fermentation, water content of 92 to 94% (according to a normal pressure heating drying method), and phosphorus of about 300 to 400 mg / 100 g (according to a vanad molybdenum analysis method). .), General live bacteria, E. coli,
Mold, yeast and arsenic, lead, cadmium and tin were not detected.
【0013】本活性酸素抑制組成物及び血圧抑制剤の試
験品1としては、上記発酵水溶液100重量部に対し
て、3重量部の緑茶抽出エキス(水又はエタノール抽出
液、固形分濃度;47〜48重量%、比重;1.07〜
1.09)を配合したもの(蒸発残分比が発酵水溶液分
/抽出エキス分=100:20)を用いた。尚、この固
形分濃度はBrix値として求め、エタノール及びグリ
セリン(主としてエタノール)濃度が約50重量%、水
濃度が約2.6重量%である。As the test product 1 of the present active oxygen-suppressing composition and blood pressure suppressing agent, 3 parts by weight of green tea extract (water or ethanol extract, solid content concentration; 48% by weight, specific gravity; 1.07 to
1.09) was blended (evaporation residue ratio: fermentation aqueous solution content / extracted extract content = 100: 20). The solid content concentration was determined as a Brix value, and the concentration of ethanol and glycerin (mainly ethanol) was about 50% by weight, and the concentration of water was about 2.6% by weight.
【0014】(2)性能評価 (A)活性酸素抑制作用について 以下の条件下において、H2O2に関する試験(表1、
表2)、OHに関する試験(表3)、O2−キサンチン
系における試験(表4)を行い、その結果を各表に示し
た。テスト品としては、上記試験品1としては水による
5倍希釈液を使用した。(2) Performance Evaluation (A) Regarding Active Oxygen Suppression Action A test on H 2 O 2 under the following conditions (Table 1,
Table 2), a test for OH (Table 3), and a test in an O 2 -xanthine system (Table 4) were performed, and the results are shown in each table. As a test product, a 5-fold diluted solution with water was used as the test product 1.
【0015】[0015]
【表1】 [Table 1]
【0016】[0016]
【表2】 [Table 2]
【0017】[0017]
【表3】 [Table 3]
【0018】[0018]
【表4】 [Table 4]
【0019】以上の表1〜4に示すように、本試験品1
においては、コントロール品と比べて活性酸素抑制作用
に優れることを示している。尚、以上より活性酸素抑制
活性は、460ユニット/ml(1カップ10ml)と
いえる。更に、発酵水溶液及び緑茶抽出エキスの相乗効
果について以下のような試験をした。即ち、下記の配合
割合からなる各試料(No.A〜C)を調製した。 上記各試料を、以下に示す測定方法により活性酸素抑制
活性を測定したAs shown in Tables 1 to 4 above, this test product 1
Shows that the active oxygen suppressing action is superior to that of the control product. From the above, it can be said that the active oxygen inhibition activity is 460 units / ml (1 cup 10 ml). Furthermore, the following tests were conducted for the synergistic effect of the fermented aqueous solution and the green tea extract. That is, each sample (No. A to C) having the following blending ratio was prepared. Each of the above samples was measured for active oxygen inhibition activity by the measurement method shown below.
【0020】〔活性酸素抑制活性の測定方法〕 本方法はEPR(電子スピン共鳴)装置を用いる方法で
あり、最近、(財)日本食品分析センターにて試験項
目;「スーパーオキシド消去活性」として行われるよう
になった方法である。即ち、まず、上記各均一化試料1
gに0.1Mリン酸緩衝液(pH7.8)を加え、充分
に抽出を行い抽出液を得る。その後、以下に示す試薬を
混合する。 2mMヒポキサンチン/リン酸緩衝液 50μl 5.5mM DETAPAC(diethlenetr
iaminepentaacetic acid)/リ
ン酸緩衝液35μl 抽出液或いは標準SOD(スーパーオキシドジスムター
ゼ)50μl DMPO(5,5−dimethyl−1−pyrro
line−1−oxide)15μl 0.4units/mlキサンチンオキシターゼ/リン
酸緩衝液 50μl 次いで、この混合液を、特殊偏平セル(日本電子株式会
社製、容量;約130μl)に吸い取り、ESR装置
(日本電子株式会社製、JES−FR80型)にセット
し、40秒後に掃引を開始して、以下に示すESR操作
条件にて測定を行った。尚、この活性酸素抑制活性測定
は、試料調整後1日後の溶液を測定したものである。 〔ESR操作条件〕 温度 室温 マイクロ波出力 8mW 磁場 334.7mT±5mT 変調 100kHz,0.79×0.1mT 増幅率 3.2×100 応答時間 0.1秒 掃引時間 2分[Measurement Method of Active Oxygen Suppression Activity] This method is a method using an EPR (electron spin resonance) apparatus, and has recently been carried out as a test item by the Japan Food Analysis Center; It is a method that came to be known. That is, first, each homogenized sample 1
0.1 M phosphate buffer (pH 7.8) is added to g to extract sufficiently to obtain an extract. Then, the following reagents are mixed. 2 mM hypoxanthine / phosphate buffer 50 μl 5.5 mM DETAPAC (diethnetr
iaminepentaacetic acid) / phosphate buffer 35 μl extract or standard SOD (superoxide dismutase) 50 μl DMPO (5,5-dimethyl-1-pyrro)
line-1-oxide) 15 μl 0.4 units / ml xanthine oxidase / phosphate buffer 50 μl Then, this mixed solution is sucked into a special flat cell (manufactured by JEOL Ltd., capacity: about 130 μL), and ESR device (JEOL) (Manufactured by JES-FR80, manufactured by Co., Ltd.), the sweep was started 40 seconds later, and the measurement was performed under the ESR operating conditions shown below. In addition, this active oxygen suppression activity measurement is a measurement of the solution one day after the sample preparation. [ESR operation conditions] temperature room temperature microwave output 8 mW magnetic field 334.7 mT ± 5 mT modulation 100 kHz, 0.79 × 0.1 mT amplification factor 3.2 × 100 response time 0.1 seconds sweep time 2 minutes
【0021】そして、Mn2+のピーク高と測定シグナ
ルのピーク高の比を求める。次いで、標準SOD(0〜
15units/ml)で検量線を作成し、抽出液で得
た値を内挿し試料中の消去活性を算出した。この結果は
以下の通りである。単位はUNIT/gである。「活性
相加理論値」は、試料No.A及びBの各活性酸素抑制
活性値を用いて単に積算したものである。 発酵水溶液及び緑茶抽出エキスを含むNo.Cでは、実
際の活性酸素抑制活性値が活性相加理論値の1.15倍
を示し、相乗効果をあることを示している。Then, the ratio of the peak height of Mn 2+ to the peak height of the measurement signal is determined. Then the standard SOD (0-
15 units / ml), a calibration curve was prepared, and the values obtained from the extract were interpolated to calculate the erasing activity in the sample. The results are as follows. The unit is UNIT / g. “Activity additive theoretical value” is the sample No. It is simply integrated by using the respective active oxygen inhibition activity values of A and B. No. containing the fermented aqueous solution and the green tea extract In C, the actual active oxygen suppression activity value is 1.15 times the theoretical value of active addition, indicating that there is a synergistic effect.
【0022】(B)ラットの血圧上昇期における血圧の
変動について 以下の条件下において、上記発酵水溶液100重量部に
対して、上記緑茶抽出エキス1.5重量部を配合したも
のを試験品2とし、この試験品2の投与による血圧の変
動を評価した。その結果を図1に示す。(B) Fluctuations in blood pressure during elevated blood pressure in rats Under the following conditions, 100 parts by weight of the fermentation aqueous solution was mixed with 1.5 parts by weight of the green tea extract to give a test product 2. The change in blood pressure due to the administration of this test product 2 was evaluated. The result is shown in FIG.
【0023】〔試験条件〕 動物:ラット;対照用・雄3匹、試験品用・雄4匹、
計7匹。そして、このラットの齢は6週齢で、その血圧
は150mmHg以上である。尚、このラットは3週齢
より血圧が上がる遺伝的性質を持つラット(以下、SH
Rという。)である。 試験投与法:給水ピンにより自由摂取。 室内:温度 23±1℃、湿度 50%±10%。 飲料:上記試験品2(SOD対応)の10%溶液にグ
ルコース及びクエン酸を入れ飲みやすくした。 血圧測定;1回/2週。 使用飼料;いずれも共通の飼料(オリエンタル酵母社
製「MF」)を用いた。 この結果によれば、対照群と比べて、本試験品2を用い
る場合は、血圧上昇を抑制する効果があることを示して
いる。[Test conditions] Animal: rat; 3 males for control, 4 males for test product,
7 in total. The age of this rat is 6 weeks, and its blood pressure is 150 mmHg or higher. It should be noted that this rat has a genetic property that blood pressure increases from 3 weeks of age (hereinafter referred to as SH
Called R. ). Test administration method: Free intake by water supply pin. Indoor: Temperature 23 ± 1 ° C, humidity 50% ± 10%. Beverage: Glucose and citric acid were added to a 10% solution of the test product 2 (corresponding to SOD) to make it easy to drink. Blood pressure measurement; once every 2 weeks. Feed used: Common feed (“MF” manufactured by Oriental Yeast Co., Ltd.) was used in all cases. The results show that the use of this test product 2 has an effect of suppressing an increase in blood pressure as compared with the control group.
【0024】(C)ラットの高血圧完成期における血圧
の変動について 以下の条件以外は上記と同じ条件により、試験品2の投
与による血圧の変動を評価した。その結果を図2に示
す。〔試験条件〕動物:ラット(上記SHR);対照
用・雄4匹、試験品用・雄4匹、計8匹。そして、この
ラットの齢は12〜15週齢で、その血圧は180mm
Hg以上である。これ以外の条件は、上記と同じであ
る。この結果によれば、図2に示すように、高血圧を抑
制する効果あると同時に投与時間の経過に伴って抑制効
果に優れることを示している。(C) Fluctuation of blood pressure in the hypertension completion stage of rats The fluctuation of blood pressure due to administration of Test Product 2 was evaluated under the same conditions as above except the following conditions. The result is shown in FIG. [Test conditions] Animal: rat (SHR above); 4 males for control, 4 males for test product, 8 in total. The age of this rat is 12 to 15 weeks, and its blood pressure is 180 mm.
It is Hg or more. The other conditions are the same as above. According to this result, as shown in FIG. 2, it has an effect of suppressing hypertension and, at the same time, an excellent suppressing effect with the passage of administration time.
【0025】(D)モニター試験 上記発酵水溶液60重量部、上記緑茶抽出エキス1.2
重量部及びオリゴ糖14重量部、主に他は精製水からな
る試験品(10ml入りポーション)を人に使用すると
いうモニター試験をした所、以下のような良好な結果を
得た。 A(58才、女性) 〔モニター開始前の症状〕顔が黒ずんでいて、階段の昇
り降りが大変つらく、血圧も165と高く降下剤を常飲
していた。 〔毎日2個飲料後の結果〕1週間ほどで足が軽くなっ
た。降下剤は止め、3週間ほどで血圧が130になっ
た。2ヵ月で、顔が見違えるほど白くなる。10才は若
く見えるようになった。(D) Monitor test 60 parts by weight of the above fermented aqueous solution, 1.2 of the above green tea extract
The following good results were obtained as a result of a monitor test in which a test product (10 ml portion) containing 10 parts by weight of oligosaccharide and mainly other parts of purified water was used for humans. A (58 years old, female) [Symptoms before the start of the monitor] His face was dark, the climbing of stairs was very difficult, his blood pressure was 165, and he was constantly taking a depressant. [Results after 2 drinks daily] My legs became lighter in about 1 week. The antihypertensive drug was stopped and the blood pressure became 130 in about 3 weeks. After two months, my face turns white so much that I can't see it. The 10-year-old started to look younger.
【0026】B(70才、男性) 〔モニター開始前の症状〕日常でも心肺機能が弱いため
階段を昇ると息が切れて、足も引きずるようだった。 〔毎日3個(朝・昼・晩)飲料後の結果〕2週間ほど
で、体が軽く感じられ始める。1ヵ月ほどで、階段を昇
っても息が切れなくなる。4ヵ月後に病院で心肺機能を
見てもらったところかなりよくなっている。この冬は始
めて、風邪をひかずに入院の必要はなく元気であった。B (70 years old, male) [Symptoms before the start of the monitor] Even in everyday life, my cardiorespiratory function was weak, so when I climbed the stairs, I felt out of breath and dragged my legs. [Results after 3 daily drinks (morning, noon, evening)] In about 2 weeks, the body begins to feel light. After about a month, I can't breathe out even when I climb the stairs. Four months later, when I was asked to see cardiopulmonary function at the hospital, it was much better. For the first time this winter, I was fine without having to be hospitalized without catching a cold.
【0027】C(52才、女性) 〔モニター開始前の症状〕高血圧で糖尿病や便秘に悩ま
されていた。血圧は上が180で下が95である。 〔毎日2個(2ヵ月間)その後毎日1個飲料後の結果〕
4日目より尿が今までの2倍ほど出るようになり体の調
子も良くなる。宿便も3日に一度出るようになる。その
後2日に一度になる。2ヵ月後に医師から血圧降下剤を
飲まなくても良いと言われる。血圧は、上が145、下
が78になり、薬を必要としなくなった。C (52 years old, female) [Symptoms before starting monitoring] He was suffering from diabetes and constipation due to high blood pressure. The blood pressure is 180 at the top and 95 at the bottom. [Results after 2 daily drinks (for 2 months) then 1 daily drink]
From the 4th day, urine is about twice as much as before and my body is feeling better. The stools will also appear once every three days. Then every two days. Two months later, my doctor tells me that I don't have to take blood pressure lowering drugs. His blood pressure was 145 on the upper side and 78 on the lower side, and he no longer needed medicine.
【0028】D(23才、女性) 〔モニター開始前の症状〕幼少の頃より便秘がひどく1
0日から2週間に1回の通便であった。顔にも細かい吹
出物が常にあり、皮膚もカサカサとした状態であった。
どちらかと言うと細身であるが下腹部が幼児体形のよう
に突き出ていて、かなり悩んでいた。 〔最初の2日5個その後毎日2個飲料後の結果〕翌日の
朝、通便があった。それより毎日通便がある。1ヵ月半
後には、顔のブツブツが全くなくなり、肌がつややかに
なった。化粧のりがとても良くなった。D (23 years old, female) [Symptoms before the start of monitoring] Constipation was severe 1 from an early age.
She had a flight once every two weeks from the 0th day. There were always small pimples on the face, and the skin was dry.
It was rather slender, but the lower abdomen was protruding like an infant figure, and I was considerably worried. [Results after 5 drinks for the first 2 days and 2 drinks every day] The following morning, there was a bowel movement. There are daily flights than that. After a month and a half, my face was completely smooth and my skin was shiny. The makeup glue has improved very much.
【0029】E(70才、女性) 〔モニター開始前の症状〕血圧200の高血圧のため入
院していた。 〔毎日2個(朝・晩)飲料後の結果〕10日ほどで血圧
が下がり、退院することができた。現在140である。E (70 years old, female) [Symptoms before the start of monitoring] He was hospitalized for high blood pressure of 200. [Results after 2 daily drinks (morning and evening)] Blood pressure dropped in about 10 days and I was able to be discharged from the hospital. Currently 140.
【0030】F(68才、女性) 〔モニター開始前の症状〕疲れが残り体がだるく、体も
固くなっていた。 〔毎日2個(朝・夕)飲料後の結果〕2日目より肌がし
っとりして化粧のりが良くなった。2週間目より疲れも
抜けて、体が軽く思うように動くようになった。F (68 years old, female) [Symptoms before the start of monitoring] My body was tired and tired and my body was stiff. [Results after 2 daily drinks (morning and evening)] Moisturized skin and improved makeup paste from the 2nd day. I was less tired than in the second week and I started to move as I wanted.
【0031】G(45才、男性) 〔モニター開始前の症状〕糖尿病で度々2〜3週間の入
院を繰り返していて、その治療中に肝臓を痛めた。 〔毎日2個飲料後の結果〕2ヵ月後肝臓は、完全に良く
なったと医師に言われ4ヵ月後糖尿病も良くなり、仕事
ができるまでになり社会復帰ができた。入院の必要はな
くなった。G (male, 45 years old) [Symptoms before starting monitoring] Diabetes was frequently hospitalized for 2 to 3 weeks, and the liver was hurt during the treatment. [Results after 2 daily drinks] After 2 months, my doctor told me that my liver had completely improved, and after 4 months I had better diabetes, and I was able to get back to work by returning to work. There is no need for hospitalization.
【0032】(E)実施例の効果のまとめ 上記のように、本発酵水溶液は有害な菌及び重金属は認
められず、且つ完全な天然原料による自然発酵物のた
め、安全である。そして、上記結果に示すように、活性
酸素抑制作用に優れるので、上記のように血圧抑制効果
に優れる結果を示している。尚、この活性酸素抑制作用
に優れることから、血圧抑制効果以外にも、この活性酸
素抑制作用に起因する効果は、同様に期待されるものと
いえる。更に、この発酵水溶液は、上記緑茶抽出エキス
を体内に有効に取り込む作用があるものと、本発明者等
は考えている。この点は、今後の詳細な研究を待つ必要
があるが、いずれにしても、本発酵水溶液と緑茶抽出エ
キスを併用すれば、活性酸素抑制作用に優れるととも
に、安心して人が飲用でき、更に人体にとって大変有用
である。また、発酵水溶液(若しくはその蒸発残分)及
び水溶性緑茶抽出エキス(若しくはその蒸発残分)は、
いずれも水溶性のため、前述の試験に示すように水に溶
解させて水溶液飲料、食品等として使用することがで
き、そのため体内での吸収に優れるといえる。更に、上
記(D)のモニター試験に示すように、ポーション(フ
レッシュミルクを入れている小さな容器形状をいう。)
型容器にこの試験品(水溶液)を入れた飲料(食品)と
して試験しているように、種々の水溶液商品(飲料、ド
リンク剤等)とすることも容易である。(E) Summary of Effects of Examples As described above, the main fermentation aqueous solution is safe because harmful bacteria and heavy metals are not recognized and the fermented aqueous solution is a natural fermented product of completely natural raw materials. Further, as shown in the above results, since the active oxygen suppressing effect is excellent, the results show that the blood pressure suppressing effect is excellent as described above. Since it is excellent in this active oxygen suppressing effect, it can be said that, in addition to the blood pressure suppressing effect, the effects resulting from this active oxygen suppressing effect are expected in the same manner. Furthermore, the present inventors believe that this fermented aqueous solution has a function of effectively incorporating the green tea extract into the body. Regarding this point, it is necessary to wait for further detailed research, but in any case, if the main fermentation aqueous solution and the green tea extract are used in combination, the active oxygen suppression effect is excellent, and it can be safely consumed by humans and Very useful for Further, the fermentation aqueous solution (or its evaporation residue) and the water-soluble green tea extract (or its evaporation residue) are
Since all of them are water-soluble, they can be dissolved in water to be used as an aqueous beverage, food, etc. as shown in the above-mentioned test, and therefore can be said to be excellently absorbed in the body. Further, as shown in the monitor test of (D) above, a portion (refers to a small container shape containing fresh milk).
As being tested as a beverage (food) in which the test product (aqueous solution) is placed in a mold container, various aqueous solution products (beverages, drinks, etc.) can be easily prepared.
【0033】尚、本発明においては、上記具体的実施例
に示すものに限られず、目的、用途に応じて本発明の範
囲内で種々変更した実施例とすることができる。即ち、
上記発酵水溶液等と水溶性緑茶抽出エキス等とからなる
組成物は、吸液性粉末等に含浸させた粉末品、造粒
品、他の粉末成分(増量剤等)に配合してなる錠剤、
又はマイクロカプセル、ソフトカプセル、ハードカプ
セル、あめ、ゼリー、及びビスケット等に充填若しくは
配合させたもの等として利用できる。また、これらの組
成物を所定容器に充填してなる商品形態についても、特
に限定されず、例えば、上記実施例にて言及しているよ
うなポーション型でもよいし、他形状容器に充填しても
よいし、粉末品をスティック状容器(袋)に充填したも
のでもよいし、更に、従来の清涼飲料水、ドリンク剤、
乳製品、油剤化製品等に配合、分散して使用してもよ
い。尚、この分散は油中水型、水中油型を問わない。The present invention is not limited to the specific examples described above, and various modifications may be made within the scope of the present invention depending on the purpose and application. That is,
The composition consisting of the above fermented aqueous solution and the water-soluble green tea extract, etc. is a powder product impregnated with a liquid-absorbent powder, a granulated product, a tablet prepared by blending with other powder components (filler etc.),
Alternatively, it can be used as a microcapsule, a soft capsule, a hard capsule, a candy, a jelly, a biscuit or the like filled or blended. Further, the product form obtained by filling these compositions in a predetermined container is not particularly limited, and may be, for example, a potion type as mentioned in the above examples, or a container having another shape. It may be a powdery product filled in a stick-shaped container (bag), or may be a conventional soft drink, a drink,
You may mix and disperse in a dairy product, an oil-ized product, etc., and may use it. The dispersion may be water-in-oil type or oil-in-water type.
【0034】[0034]
【発明の効果】本発明の組成物は活性酸素抑制効果に優
れる。従って、この活性酸素抑制組成物の使用により、
活性酸素が原因となる各種の病気、例えば、血流障害に
よる病気(心筋梗塞、脳卒中、高血圧、生理痛、肩こ
り、神経痛、腰痛、二日酔い等)、成人病・内科疾患
(癌、腎炎、肝炎、糖尿病等)、美容・皮膚病(しみ、
そばかす、肌荒れ、冷え症、便秘、しわ、アトピー性皮
膚炎等)等の治療、改良等に優れた効果を発揮するもの
と考えられる。また、本発明の製造方法によれば、活性
酸素抑制効果に優れる水溶性組成物を容易に製造、調製
できる。本発明の血圧抑制剤は、血圧の抑制効果に優れ
る。更に、本発明は水溶性の活性酸素抑制組成物及び血
圧抑制剤であるので、吸収効果に優れるとともに、水溶
性飲料・食品等としてその適用分野が広くなる。The composition of the present invention has an excellent effect of suppressing active oxygen. Therefore, by using this active oxygen suppressing composition,
Various diseases are active oxygen causes, for example, diseases caused by blood flow disorders (myocardial infarction, stroke, high blood pressure, menstrual cramps, shoulder stiffness, neuralgia, low back pain, hangover, etc.), adult diseases, medical diseases (cancer, nephritis, hepatitis , Diabetes, etc., beauty / skin diseases (stains,
It is considered to exert an excellent effect on the treatment and improvement of freckles, rough skin, coldness, constipation, wrinkles, atopic dermatitis, etc.). Further, according to the production method of the present invention, a water-soluble composition having an excellent effect of suppressing active oxygen can be easily produced and prepared. The blood pressure inhibitor of the present invention has an excellent blood pressure inhibitory effect. Further, since the present invention is a water-soluble active oxygen-suppressing composition and a blood pressure-suppressing agent, it has excellent absorption effects and can be applied to a wide range of fields such as water-soluble beverages and foods.
【0035】また、特に、本発明に主成分として用いら
れる発酵水溶液は、完全な天然原料による自然発酵物の
ため、有害な菌及び重金属は認められず、安全であると
ともに本来、活性酸素抑制及び血圧抑制として有用な米
糠及び大豆製品を原料としているので、且つ有用な窒素
化合物(アミノ酸等)、灰分、リン化合物等が含まれて
いるので、大変バランスの良い活性酸素抑制組成物及び
血圧抑制剤である。更に、緑茶抽出エキスも天然物を利
用したもののため、これを含む活性酸素抑制組成物及び
血圧抑制剤の安全性も優れる。In particular, since the fermented aqueous solution used as the main component in the present invention is a natural fermented product of completely natural raw materials, harmful bacteria and heavy metals are not observed, and it is safe and originally it has a function of suppressing active oxygen. Since rice bran and soybean products useful for blood pressure control are used as raw materials and they also contain useful nitrogen compounds (amino acids, etc.), ash, phosphorus compounds, etc., a very well-balanced active oxygen suppressing composition and blood pressure suppressing agent. Is. Furthermore, since the green tea extract also uses a natural product, the active oxygen suppressing composition and the blood pressure suppressing agent containing it are excellent in safety.
【図1】実施例におけるSHRの血圧上昇期における血
圧の変動を示すグラフである。FIG. 1 is a graph showing changes in blood pressure during SHR blood pressure elevation in an example.
【図2】実施例におけるSHRの高血圧完成期における
血圧の変動を示すグラフである。FIG. 2 is a graph showing fluctuations in blood pressure in the SHR hypertension completion period in Examples.
Claims (8)
剤にてpHを7.5〜10に調整された液体培地に納豆
菌若しくは枯草菌を接種し、好気性雰囲気下において培
養させ、濾過して製造した発酵水溶液又は該発酵水溶液
の蒸発残分に、水及びエタノールのうちの少なくとも1
種を含む溶媒にて抽出してなる水溶性緑茶抽出エキス又
は該水溶性緑茶抽出エキスの蒸発残分を含有させてなる
ことを特徴とする活性酸素抑制組成物。1. A liquid medium containing rice bran, soybeans and water, and having a pH adjusted to 7.5 to 10 with an alkaline agent, inoculated with Bacillus subtilis natto or Bacillus subtilis and cultured in an aerobic atmosphere, At least one of water and ethanol is added to the fermentation aqueous solution produced by filtration or the evaporation residue of the fermentation aqueous solution.
A composition for suppressing active oxygen, comprising a water-soluble green tea extract extract extracted with a solvent containing seeds, or an evaporation residue of the water-soluble green tea extract extract.
算にて、上記発酵液の蒸発残分100重量部に対して1
〜50重量部配合される請求項1記載の活性酸素抑制組
成物。2. The green tea extract is 1 in terms of the evaporation residue, based on 100 parts by weight of the evaporation residue of the fermentation liquor.
The active oxygen suppressing composition according to claim 1, which is mixed in an amount of -50 parts by weight.
剤にてpHを7.5〜10に調整された液体培地に納豆
菌若しくは枯草菌を接種し、好気性雰囲気下において培
養させ、濾過して発酵水溶液を製造し、該発酵水溶液
に、水及びエタノールのうちの少なくとも1種を含む溶
媒にて抽出して製造された水溶性緑茶抽出エキスを配合
して、水溶液状の活性酸素抑制組成物を製造することを
特徴とする活性酸素抑制組成物の製造方法。3. A liquid medium containing rice bran, soybeans and water, and having a pH adjusted to 7.5 to 10 with an alkaline agent, inoculated with Bacillus natto or Bacillus subtilis and cultured in an aerobic atmosphere, A fermented aqueous solution is produced by filtering, and the fermented aqueous solution is mixed with a water-soluble green tea extract extract produced by extraction with a solvent containing at least one of water and ethanol to suppress the active oxygen in the form of an aqueous solution. A method for producing an active oxygen-suppressing composition, which comprises producing the composition.
00重量部とする場合、10〜20重量部である請求項
3記載の活性酸素抑制組成物の製造方法。4. The blending ratio of the soybeans is the rice bran 1
The method for producing an active oxygen suppressing composition according to claim 3, wherein the amount is 10 to 20 parts by weight when the amount is 00 parts by weight.
求項3又は4記載の活性酸素抑制組成物の製造方法。5. The method for producing an active oxygen suppressing composition according to claim 3, wherein the pH during culture is 8 to 10.
算にて、上記発酵液の蒸発残分100重量部に対して1
〜50重量部配合される請求項3乃至5のいずれかに記
載の活性酸素抑制組成物の製造方法。6. The green tea extract is 1 in terms of evaporation residue, based on 100 parts by weight of the evaporation residue of the fermentation broth.
The method for producing the active oxygen suppressing composition according to any one of claims 3 to 5, which is mixed in an amount of -50 parts by weight.
剤にてpHを7.5〜10に調整された液体培地に納豆
菌若しくは枯草菌を接種し、好気性雰囲気下において培
養させ、濾過して製造した発酵水溶液又は該発酵水溶液
の蒸発残分に、水及びエタノールのうちの少なくとも1
種を含む溶媒にて抽出してなる水溶性緑茶抽出エキス又
は該水溶性緑茶抽出エキスの蒸発残分を含有させてなる
ことを特徴とする血圧抑制剤。7. A liquid medium containing rice bran, soybeans and water and adjusted to pH 7.5 to 10 with an alkaline agent is inoculated with Bacillus subtilis natto or Bacillus subtilis and cultured in an aerobic atmosphere. At least one of water and ethanol is added to the fermentation aqueous solution produced by filtration or the evaporation residue of the fermentation aqueous solution.
A blood pressure suppressor comprising a water-soluble green tea extract extract extracted with a solvent containing seeds, or an evaporation residue of the water-soluble green tea extract extract.
算にて、上記発酵液の蒸発残分100重量部に対して1
〜50重量部配合される請求項7記載の血圧抑制剤。8. The green tea extract is 1 in terms of the evaporation residue, based on 100 parts by weight of the evaporation residue of the fermentation broth.
The blood pressure suppressing agent according to claim 7, which is mixed in an amount of -50 parts by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4199082A JPH0840B2 (en) | 1991-10-31 | 1992-07-01 | Active oxygen suppressing composition, method for producing the same, and blood pressure suppressing agent |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP31364991 | 1991-10-31 | ||
| JP3-313649 | 1991-10-31 | ||
| JP4199082A JPH0840B2 (en) | 1991-10-31 | 1992-07-01 | Active oxygen suppressing composition, method for producing the same, and blood pressure suppressing agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH06284872A JPH06284872A (en) | 1994-10-11 |
| JPH0840B2 true JPH0840B2 (en) | 1996-01-10 |
Family
ID=26511330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4199082A Expired - Lifetime JPH0840B2 (en) | 1991-10-31 | 1992-07-01 | Active oxygen suppressing composition, method for producing the same, and blood pressure suppressing agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0840B2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR970005301A (en) * | 1995-07-28 | 1997-02-19 | 아키히코 키무라 | Blood pressure inhibitors with superoxide dismutase action |
| JPH0948732A (en) * | 1995-08-04 | 1997-02-18 | Pola Chem Ind Inc | Activated oxygen scavenging agent and composition containing the same |
| JPH09309833A (en) * | 1996-05-22 | 1997-12-02 | Toyo Hakko:Kk | Active oxygen suppressing composition, method for producing the same, and blood pressure suppressing agent |
| US6030622A (en) * | 1998-06-23 | 2000-02-29 | Shehadeh; Ahmad Abdallah | Herbal extract composition and method with immune-boosting capability |
| WO2000069453A1 (en) * | 1999-05-13 | 2000-11-23 | Toyo Hakko Co., Ltd. | Sod-like composition and blood-pressure controlling agent |
| JP4841718B2 (en) * | 2000-07-25 | 2011-12-21 | 株式会社東洋発酵 | Antiallergic and antioxidants |
| JP4854841B2 (en) * | 2000-09-18 | 2012-01-18 | 株式会社東洋発酵 | Liver disorder reducing agent |
| WO2003013565A1 (en) * | 2001-08-08 | 2003-02-20 | Toyo Hakko Co., Ltd. | Functional materials, sod agonists, hypotensives and thrombolytics, process for producing the same and microbial strains to be used therein |
| KR100476302B1 (en) * | 2002-01-05 | 2005-03-15 | 주식회사 빙그레 | Preventive Yogurt against Adult Diseases and Method for Producing the same |
| JP5280672B2 (en) * | 2007-12-18 | 2013-09-04 | 株式会社 Tiens Japan | Beta-glucan peptide derivatives exhibiting action to eliminate harmful substances |
| JP5855375B2 (en) * | 2011-07-13 | 2016-02-09 | 株式会社東洋発酵 | Anti-fatigue composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2610325B2 (en) * | 1988-12-05 | 1997-05-14 | 拓壬 中村 | Active oxygen suppression composition |
-
1992
- 1992-07-01 JP JP4199082A patent/JPH0840B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06284872A (en) | 1994-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2631850C (en) | Equol-containing fermentation product of soybean embryonic axis, and method for production thereof | |
| JP2003259835A (en) | Manufacture and use of fermented products | |
| JP4596304B2 (en) | Growth hormone secretion promoting composition | |
| JPH0840B2 (en) | Active oxygen suppressing composition, method for producing the same, and blood pressure suppressing agent | |
| WO2009123364A1 (en) | Mineral absorption accelerator and iron deficiency anemia improver or food composition | |
| US5776756A (en) | Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity | |
| US20020018818A1 (en) | Sugar decomposition inhibitor, digestive enzyme activity inhibitor, insulin secretion controller, and healthy food and beverage | |
| JPH0881381A (en) | Health and beauty-promoting agent having sod action, blood pressure-suppressing agent and constipation-improving agent | |
| JP2001136959A (en) | Culture product containing bacillus subtilis cell and/or product thereof, water-soluble vitamin k derivative originated from the same, medicine, food and feed containing the same and method for producing the same | |
| JP2010100663A (en) | Enzyme inhibitor containing fermentation product of allium cepa l | |
| KR102691084B1 (en) | A composition for improving and preventing obesity comprising complex-fermented fruits of Cudrania tricuspidata and its preparation method | |
| JP2005097222A (en) | Fermented onion | |
| JP3668722B2 (en) | Antioxidant composition | |
| JP2004043505A (en) | Fermentation composition and antioxidant composition containing the fermentation composition | |
| KR20220054023A (en) | A composition for immune enhancement comprising benicasa hispida extract | |
| US20040137602A1 (en) | Method for incubating Pleurotus nebrodensis and disease preventing/treating agents from Pleurotus nebrodensis | |
| KR100687546B1 (en) | Composition having SOD action, and blood pressure inhibitor containing the same | |
| KR101904448B1 (en) | Honey Black Food | |
| JPH09309833A (en) | Active oxygen suppressing composition, method for producing the same, and blood pressure suppressing agent | |
| KR0166130B1 (en) | Fermentation Composition with Superoxide Dismutase Activity | |
| JPWO2000069453A1 (en) | SOD-like composition and blood pressure suppressant | |
| JP2005022988A (en) | Muscle cell sugar transport enhancing composition containing mugwort as an active ingredient | |
| JPH06315359A (en) | Fermentation composition having sod action | |
| CN110075128A (en) | A kind of pharmaceutical compositions for being used to enhance immune function comprising enzyme treated bee milk powder as effective component | |
| JP2005237300A (en) | Food material and manufacturing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090110 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100110 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110110 Year of fee payment: 15 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110110 Year of fee payment: 15 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120110 Year of fee payment: 16 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130110 Year of fee payment: 17 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130110 Year of fee payment: 17 |